Scorpius Holdings, Inc. Announces Closing of Public Offering
May 16 2024 - 4:15PM
Scorpius Holdings, Inc. (NYSE American: SCPX), (“Scorpius” or the
“Company”), an integrated contract development and manufacturing
organization (CDMO), today announced the closing of its
underwritten public offering of 60,000,000 common units and/or
pre-funded units in lieu thereof. Each common (or pre-funded) unit
was offered at a public offering price of $0.10 per unit (inclusive
of the pre-funded warrant exercise price) and consists of one share
of common stock (or pre-funded warrant to purchase one share of
common stock in lieu thereof) and a common warrant, for gross
proceeds of $6,000,000, before deducting underwriting discounts and
offering expenses. The warrants have an exercise price of $0.12 per
share and are immediately exercisable upon issuance for a period of
five years following the date of issuance. In addition, the Company
has granted the underwriters a 45-day option to purchase up to an
additional 9,000,000 shares of common stock (and/or pre-funded
warrants) and/or up to an additional 9,000,000 common warrants
solely to cover over-allotments, if any.
The Company intends to use the net proceeds of
the offering to fund working capital, general corporate purposes,
and the repayment of a $750,000 non-convertible promissory note,
plus accrued and unpaid interest.
ThinkEquity acted as sole book-running manager
for the offering.
A registration statement on Form S-1 (File No.
333-279092) relating to the shares of common stock, pre-funded
warrants, common warrants, and the shares of common stock
underlying such warrants was filed with the Securities and Exchange
Commission (“SEC”) and became effective on May 13, 2024. This
offering is being made only by means of a prospectus. Copies of the
final prospectus may be obtained from ThinkEquity, 17 State Street,
41st Floor, New York, New York 10004.
This press release shall not constitute an offer
to sell or a solicitation of an offer to buy, nor shall there be
any sale of these securities in any state or jurisdiction in which
such an offer, solicitation or sale would be unlawful prior to
registration or qualification under the securities laws of any such
state or jurisdiction.
About Scorpius Holdings,
Inc.
Scorpius Holdings Inc. is an integrated large
molecule contract development and manufacturing organization (CDMO)
focused on rapidly advancing biologic and cell therapy programs to
the clinic and beyond. Scorpius offers a broad array of analytical
testing, process development, and manufacturing services to
pharmaceutical and biotech companies at its state-of-the-art
facilities in San Antonio, TX. With an experienced team and new,
purpose-built U.S. facilities, Scorpius is dedicated to transparent
collaboration and flexible, high-quality biologics
biomanufacturing. For more information, please visit
www.scorpiusbiologics.com.
Forward-Looking Statements
This release contains forward-looking statements
within the meaning of the Private Securities Litigation Reform Act
of 1995. In some cases forward-looking statements can be identified
by terminology such as "may," "should," "potential," "continue,"
"expects," "anticipates," "intends," "plans," "believes,"
"estimates," and similar expressions and include statements
regarding the intended use of proceeds. Important factors that
could cause actual results to differ materially from current
expectations include, among others, the factors described in the
Company’s annual report on Form 10-K for the year ended December
31, 2023 and any other filings the Company makes with the SEC. The
information in this presentation is provided only as of the date
presented, and the Company undertakes no obligation to update any
forward-looking statements contained in this press release on
account of new information, future events, or otherwise, except as
required by law.
For Investor Relations
Inquiries:
David Waldman+1
(919)-289-4017investorrelations@nighthawkbio.com
Scorpius (AMEX:SCPX)
Historical Stock Chart
From Sep 2024 to Oct 2024
Scorpius (AMEX:SCPX)
Historical Stock Chart
From Oct 2023 to Oct 2024